JCB, Volume 21, Number 2, 2015 Commentary Vol.21 No. 2 (2015) Labels, Lawyers, & Logic Peter J. Pitts America deserves access to high-quality health care without avoidable medical errors and complications. This achievable goal begins with harnessing and using the power of information. And Commentary Vol.21 No. 2 (2015) Improper Handling of Harmful Chemicals by Small Tea Growers of Assam: Challenge to Heath and Local Environment Dhrubajyoti Gogoi After dominating the world tea market since last 170 years, today India became the fourth largest tea exporter. The state Assam, located in the Northeastern end of the country contributes Article Vol.21 No. 2 (2015) Trends in Market Access for Specialty Biologics: Challenges & Promises Sanjay Kumar Rao Specialty biologics are the fastest growing class of bio/pharmaceutical products in terms of the number of new brand launches and rates of health care spending in the U.S. and globally. I Article Vol.21 No. 2 (2015) Human Health Biotechnology: Can Brazil Advance? Carlos Torres Freire The Brazilian human health biotechnology sector was analyzed according to its spacial and sectorial distribution of the following aspects: (i) the scientific production; (ii< Article Vol.21 No. 2 (2015) Importance of venture capital investors for the industrial biotechnology industry Gunter Festel From the Classroom Vol.21 No. 2 (2015) The University of Colorado Certificate Program in Bioinnovation and Entrepreneurship: An Update and Current Status Madhavan Parthasarathy The purpose of this paper is to provide an update and report the current status of the cross-campus University of Colorado Denver program in bioinnovation and entrepreneurship, details of Case Study Vol.21 No. 2 (2015) Accelerating the Growth of Bioeconomy in Malaysia Nazlee Kamal Advances in commercial application of biotechnology worldwide over the past two decades have led to the development of a bioeconomy, whereby substantial economic outputs are from the deve Case Study Vol.21 No. 2 (2015) Lean Start-up: A Comprehensive Case Study in the Establishment of Affordable Laboratory Infrastructure Kristopher James Grohn Historically, innovation in the biotechnology sector has relied to a large extent on the expensive infrastructure provided by universities or large pharmaceutical companies. This prohibit From the Boardroom Vol.21 No. 2 (2015) Early Commercial Assessments: An Innovative Tactic for Small Biotechs Anthony Giovinazzo As a small biotech company embarks on a drug development program, there is a tendency for management to focus on a well-defined set of issues. Is the science behind the drug valid? Does i Legal and Regulatory Updates Vol.21 No. 2 (2015) Which Types of Bioinformatics Inventions Are Eligible for Patent Protection? Trent Ostler The field of bioinformatics is flourishing, and strong growth is only projected to continue. Like any cutting edge technology, bioinformatics requires an integrated IP strategy involving
